Rafina Innovations Inc. (VICA) Stock Price & Analysis
Educational signal · not a buy or sell recommendation · How to read this
For informational purposes only. Not financial advice. Machine-generated analysis by Stock Expert AI — model gemini-2.5-flash, generated Jun 15, 2026. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief. Data sources: Financial Modeling Prep, Yahoo Finance, SEC EDGAR
Quick AnswerRafina Innovations Inc. (VICA) trades at $0.001. Rafina Innovations Inc. is a UK-based medical technology company focused on developing, researching, commercializing, and marketing medical devices. Sector: Healthcare.
Price as of · Last analyzed: Jun 15, 2026Analyst Coverage for VICA: VICA does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage.
No score published: we hold no usable price for this ticker, and a grade beside a missing price says nothing.
Rafina Innovations Inc. (VICA) Healthcare & Pipeline Overview
Rafina Innovations Inc. is a UK-based medical technology firm specializing in the development, research, commercialization, and marketing of medical devices and innovative methods. It also manages rehabilitation clinics for prosthetics, orthotics, and diabetic foot care across Southern Europe, the Middle East, and North Africa, licensing its proprietary advancements in diverse medical fields.
What Is the Investment Thesis for VICA?
Rafina Innovations Inc. operates with a dual-division model, combining specialized rehabilitation clinics with a technology development arm, which serves as a key value driver. The Clinic division provides direct patient engagement and potential revenue streams from prosthetics, orthotics, and diabetic foot care services across Southern Europe, the Middle East, and North Africa. The Technology division, focused on developing and licensing proprietary medical devices across diverse fields like bioengineering and robotic surgery, offers significant long-term growth potential through intellectual property commercialization. Growth catalysts include the successful market introduction of new medical devices, expansion of its clinic network into underserved regions, and securing strategic licensing agreements with larger industry players. The increasing global prevalence of chronic diseases, such as diabetes, underpins a growing demand for the company's specialized care and technological solutions. However, investors must consider the company's current financial profile, characterized by negative profit and gross margins (-26.9% and -5.2% respectively), indicating unprofitability and cost challenges. Its market capitalization of $0.00B suggests a micro-cap status, and a high Beta of 9.70 points to extreme stock price volatility. Furthermore, its 'OTC Other' tier listing presents challenges related to liquidity and regulatory oversight, with an unknown disclosure status.
Based on FMP financials and quantitative analysis
VICA Key Highlights
Rafina Innovations Inc. reports a negative Profit Margin of -26.9%, reflecting current unprofitability in its operations.
- The company's Gross Margin stands at -5.2%, indicating that its cost of goods sold currently exceeds its revenue from sales.
- With a Beta of 9.70, VICA exhibits extremely high volatility relative to the broader market, suggesting significant price swings.
- The company operates with a very lean team of 4 employees, indicating a highly focused or early-stage operational structure.
- Rafina Innovations Inc. has a market capitalization of $0.00B, classifying it as a micro-cap entity with limited market valuation.
Who Are VICA's Competitors?
VICA is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | MoonshotScore |
|---|---|---|---|---|
| BJDX Bluejay Diagnostics, Inc. | $0.84 | -1.12% | 30 5-pillar | |
| NVNO enVVeno Medical Corporation | $8.10 | +0.75% | $5.63M | 33 5-pillar |
| BDMD Baird Medical Investment Holdings Limited | $0.75 | +0.91% | $31.7M | — |
| SNWV SANUWAVE Health, Inc. | $4.82 | +4.33% | $41.5M | 36 5-pillar |
| SRTS Sensus Healthcare, Inc. | $2.98 | +1.02% | $49.1M | 31 5-pillar |
| HYPD Hyperion DeFi, Inc. | $3.73 | +1.91% | $56.5M | 36 5-pillar |
| LNSR LENSAR, Inc. | $6.75 | +2.74% | $82.9M | 45 5-pillar |
| APYX Apyx Medical Corporation | $2.55 | +2.00% | $107M | 33 5-pillar |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are VICA's Key Strengths?
Dual-division model combining direct patient care clinics with medical technology R&D and licensing.
- Broad scope of R&D across diverse medical fields, including high-growth areas like robotic surgery and bioengineering.
- Proprietary technological advancements and potential for intellectual property licensing.
- Established rehabilitation clinics serving specific regions in Southern Europe, Middle East, and North Africa.
What Are VICA's Weaknesses?
Very small employee base of 4, potentially limiting operational scale and R&D capacity.
- Negative profit margin (-26.9%) and gross margin (-5.2%), indicating current unprofitability and cost challenges.
- Extremely high stock volatility with a Beta of 9.70.
- Trading on the OTC Other tier, which typically entails challenges related to liquidity and regulatory oversight.
What Are the Key Risks for VICA?
Financial-distress signal — its Altman Z-Score of -7.26 sits in the distress zone (elevated bankruptcy risk).
- Negative return on equity (-55.5%) — the business is not currently generating profit on shareholder capital.
- Weak fundamentals — a Piotroski F-Score of 1/9 flags soft profitability, leverage or efficiency.
- The company currently reports negative profit and gross margins (-26.9% and -5.2% respectively), indicating sustained unprofitability and operational cost challenges.
- Extremely high stock volatility, evidenced by a Beta of 9.70, exposes investors to significant and unpredictable price fluctuations.
- Operating on the 'OTC Other' tier presents inherent risks including low liquidity, potential for wide bid-ask spreads, and limited regulatory oversight and disclosure.
- Intense competition within the highly innovative and fragmented medical devices industry could hinder market penetration and profitability for new products.
- Delays or failures in obtaining necessary regulatory approvals for new medical devices could significantly impede commercialization efforts and time-to-market.
What Threats Does VICA Face?
- Intense competition from established medical device manufacturers and other innovative startups.
- Significant regulatory hurdles and lengthy approval processes for new medical technologies.
- Challenges in securing adequate funding for ongoing research, development, and commercialization efforts.
- Market acceptance risks for new and innovative medical devices and methodologies.
What Are VICA's Competitive Advantages?
- Proprietary technological advancements and intellectual property across diverse medical fields, including bioengineering and robotic surgery.
- Integrated business model combining direct patient care through clinics with medical technology development, allowing for direct feedback and validation.
- Specialized expertise in niche medical areas such as tissue mechanics, ultrasonics, and advanced diabetic foot care.
- Geographic focus on Southern Europe, the Middle East, and North Africa for clinic operations, potentially establishing regional market presence.
What Does VICA Do?
Founded in 2007, Rafina Innovations Inc., initially known as HCi Viocare until its name change in July 2018, is a medical technology company headquartered in Glasgow, United Kingdom. The company's operations are strategically bifurcated into two distinct yet complementary divisions: its Clinic division and its Technology division. The Clinic division is dedicated to managing specialized rehabilitation clinics, providing essential services in prosthetics, orthotics, and comprehensive diabetic foot care. These clinics serve a broad patient base across Southern Europe, the Middle East, and North Africa, addressing critical needs in these regions for advanced rehabilitative care. This operational arm not only generates revenue but also provides a practical environment for understanding patient needs and potentially testing new technologies developed by the company. Simultaneously, the Technology division forms the core of Rafina Innovations Inc.'s innovation engine. This division is actively engaged in the creation, rigorous development, and strategic market introduction of cutting-edge medical devices, innovative methodologies, and advanced products. The scope of its research and development is extensive, encompassing a wide array of medical fields. These include, but are not limited to, prosthetics, orthotics, general rehabilitation, bioengineering, mobility solutions, advanced diabetes and diabetic foot care technologies, tissue mechanics, ultrasonics, sophisticated medical signal processing and analysis, general medical technology, orthopedics, and the rapidly evolving field of robotic surgery. Furthermore, a key aspect of the Technology division's strategy involves the licensing of its proprietary technological advancements, allowing for broader market penetration and revenue generation through intellectual property. With a lean team of four employees, Rafina Innovations Inc. positions itself as an agile innovator within the specialized segments of the medical technology and rehabilitation sectors.
What Products and Services Does VICA Offer?
- Develop and research advanced medical technologies and innovative methods.
- Commercialize and market proprietary medical devices and products.
- Manage specialized rehabilitation clinics for prosthetics in Southern Europe, Middle East, and North Africa.
- Operate specialized rehabilitation clinics for orthotics in Southern Europe, Middle East, and North Africa.
- Provide comprehensive diabetic foot care services through its network of rehabilitation clinics.
- Engage in bioengineering, tissue mechanics, ultrasonics, and medical signal processing research.
- Develop technologies for general rehabilitation, mobility, orthopedics, and robotic surgery.
- License its proprietary technological advancements to other entities.
How Does VICA Make Money?
- Generates revenue from the operation of specialized rehabilitation clinics offering prosthetics, orthotics, and diabetic foot care services.
- Derives income from the commercialization and direct sales of its proprietary medical devices and innovative products.
- Secures revenue through licensing agreements, allowing other companies to utilize Rafina's patented technological advancements.
- Invests in research and development to create new medical technologies, which are then commercialized or licensed.
What Industry Does VICA Operate In?
Rafina Innovations Inc. operates within the dynamic Healthcare sector, specifically targeting the Medical Devices industry. This industry is characterized by continuous innovation, stringent regulatory requirements, and a growing global demand driven by an aging population and increasing prevalence of chronic diseases. Rafina's strategic focus on specialized rehabilitation, including prosthetics, orthotics, and comprehensive diabetic foot care, positions it within a niche yet expanding segment. The global market for medical devices is projected to grow steadily, fueled by technological advancements in areas such as bioengineering, robotics, and personalized medicine. Rafina's dual approach, combining direct clinic operations with medical technology development and licensing, allows it to address both service delivery and product innovation. The competitive landscape is fragmented, featuring large multinational corporations alongside numerous specialized smaller firms. Rafina aims to differentiate itself through proprietary technological advancements and targeted regional clinic operations, particularly in Southern Europe, the Middle East, and North Africa, where specific healthcare needs may present unique opportunities.
Who Are VICA's Key Customers?
- Patients requiring specialized rehabilitation services for prosthetics and orthotics.
- Individuals seeking comprehensive diabetic foot care solutions and related medical support.
- Healthcare providers, hospitals, and clinics interested in utilizing or integrating Rafina's medical devices.
- Other medical technology companies or pharmaceutical firms looking to license advanced proprietary technologies.
Research confidence
Thin evidence — scoring coverage unknown. Treat this as a starting point, not a conclusion.
- ● Scoring coverage unknown
- ● No usable price
- ● No filing on record
- ● No analyst coverage
Key Financial Metrics
Return on equity for Rafina Innovations Inc. stands at -55.5%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is -11.4%, showing how much profit it generates from its asset base. A current ratio of 1.18 indicates the company holds enough short-term assets to cover its near-term obligations.
Company Profile
Rafina Innovations Inc. operates in the Medical - Devices industry within the Healthcare sector. It is headquartered in Glasgow, GB. The company is led by CEO Nikolaos Kardaras. VICA has traded publicly since 2013.
Financial Health
Rafina Innovations Inc.'s Piotroski F-Score is 1/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny. Its Altman Z-Score of -7.26 places it in the distress zone, a signal of elevated financial risk.
Insider Activity
12 transactions · 12 purchases, 0 sales, 0 other transactions · 1 identified insiders · most recent available transactions. Purchases and sales use the reported transaction category. Other transactions include awards, exercises, gifts, withholding and unclassified activity; an acquisition or disposition alone is not a purchase or sale. These records do not establish intent.
VICA Financials
Fundamental Snapshot
Based on FMP financials and quantitative analysis
VICA Latest News
-
Stocks That Hit 52-Week Lows On Monday
· Dec 23, 2019
VICA Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations collected by Financial Modeling Prep for VICA.
Price Targets
Wall Street price target analysis for VICA.
VICA MoonshotScore
MoonshotScore is Stock Expert AI's proprietary 0-100 research rating, not a buy or sell recommendation. No MoonshotScore is published for VICA; grades run from A+ (80-100) to F (below 30).
VICA OTC Market Information
Rafina Innovations Inc. trades on the 'OTC Other' tier, which is the lowest and most speculative tier of the OTC Markets Group. Unlike companies listed on major exchanges like NYSE or NASDAQ, which adhere to strict listing standards regarding financial health, corporate governance, and disclosure, companies on the 'OTC Other' tier have minimal reporting requirements. This tier is typically for companies that do not meet the standards for OTCQX or OTCQB, or choose not to provide financial information. This classification often indicates limited public information and higher inherent risks compared to higher-tiered OTC or exchange-listed securities.
- OTC Tier: OTC Other
- Limited Public Information: The 'OTC Other' tier implies minimal disclosure requirements, leading to a lack of comprehensive and timely financial and operational data for investors.
- Low Liquidity and High Volatility: Shares may be difficult to buy or sell, and prices can be highly volatile due to thin trading volumes and wide bid-ask spreads.
- Lack of Regulatory Oversight: Companies on this tier are subject to less stringent regulatory scrutiny compared to exchange-listed or higher-tier OTC companies, increasing investment risk.
- Potential for Penny Stock Fraud: The 'OTC Other' tier can be susceptible to manipulative practices, including 'pump-and-dump' schemes, due to limited oversight.
- Difficulty in Valuation: The absence of robust financial reporting and analyst coverage makes it challenging to accurately assess the company's intrinsic value.
- Verify any available financial statements, even if unaudited, for consistency and red flags.
- Research management's background, including any past regulatory issues or business failures.
- Scrutinize the company's business model and revenue generation, seeking specific details beyond general descriptions.
- Assess the current trading volume and bid-ask spread to understand potential liquidity challenges.
- Look for any news, press releases, or corporate actions that might provide insights into operations or financial health.
- Investigate any legal or regulatory actions against the company or its executives.
- Consider the company's ability to raise capital and its burn rate, given its negative margins.
- The company has a stated physical headquarters in Glasgow, UK, and a founding year (2007).
- It operates distinct business divisions (Clinic and Technology) with defined services and product development areas.
- The company explicitly mentions licensing proprietary technological advancements, indicating a focus on intellectual property.
- It serves specific geographic regions (Southern Europe, Middle East, North Africa) with its clinic operations.
- The company has a named CEO, Nikolaos Kardaras, despite limited background information.
What Investors Ask About Rafina Innovations Inc. (VICA) — Healthcare
What are the primary financial challenges facing Rafina Innovations Inc. given its current metrics?
Rafina Innovations Inc. faces several significant financial challenges as indicated by its current metrics. The company reports a negative Profit Margin of -26.9% and a negative Gross Margin of -5.2%, which are strong indicators of unprofitability.
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
MoonshotScore is not published for this security.
Data provided for informational purposes only.
- Information regarding the CEO's background, track record, and tenure is not available in the provided source data.
- Specific details on product lines, market share, and competitive advantages beyond general descriptions are limited.
- The disclosure status for the OTC listing is explicitly stated as 'Unknown', limiting transparency.